Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (16,423,506)	$ (14,663,529)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash consideration for acquired in-process research and development	6,541,485
Impairment charges	1,000,000	490,676
Stock-based compensation	985,260	704,425
Depreciation	181,314	146,299
Amortization	135,664	45,426
Unrealized gains on foreign currency exchange	(3,310)	31,357
Debt discount and deferred financing cost accretion		120,024
Gain on disposal of property and equipment		(3,806)
Changes in fair value of warrant liability	(30,000)	2,874,484
Changes in fair value of embedded derivatives		(183,638)
Changes in operating assets and liabilities:
Accounts receivable	2,449,447	1,258,837
Prepaid expenses and other current assets	179,298	589,773
Accounts payable	(322,976)	20,940
Accrued expenses and other current liabilities	(2,125,851)	1,695,296
Deferred revenue	(14,833)	(14,833)
Deferred rent		861,741
Lease obligation	(133,813)
Tax refund receivable	40,376	4,839,775
Deferred taxes	(58,500)	(3,046,768)
Net cash used in operating activities	(7,599,945)	(4,233,521)
CASH FLOWS FROM INVESTING ACTIVITIES:
Cash paid for short-term investments	(28,207,073)
Purchase of property and equipment	(1,227)	(968,354)
Proceeds from sale of property and equipment		14,492
Additions to intangible assets	(25,396)	(39,145)
Net cash used in investing activities	(28,233,696)	(993,007)
CASH FLOWS FROM FINANCING ACTIVITIES:
Redemption of preferred stock		(2,386,284)
Cash paid in conjunction with warrant exchange	(25,000)	(1,100,000)
Proceeds from conditional economic incentive		100,000
Proceeds from issuance of common units, net of issuance costs	12,668,784	4,334,816
Payments of notes payable	(186,940)
Proceeds from exercises of warrants and stock options	30,324	22,898
Net cash provided by financing activities	12,487,168	971,430
EFFECT OF EXCHANGE RATES ON CASH		(50,365)
Net decrease in cash and cash equivalents and restricted cash	(23,346,473)	(4,305,463)
Cash, cash equivalents and restricted cash, beginning of period	34,353,129	12,303,639
Cash, cash equivalents and restricted cash, end of period	11,006,656	7,998,176
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest		49,712
SUPPLEMENTAL NON-CASH FINANCING ACTIVITIES:
Common stock issued for acquired in-process research and development	$ 3,791,485
Notes payable issued in conjunction with the exchange of warrants		1,500,000
Settlement of warrant liability for common stock		3,345,030
Series B Redeemable Convertible Preferred Stock [Member]
SUPPLEMENTAL NON-CASH FINANCING ACTIVITIES:
Conversion of Series B redeemable convertible preferred stock into common stock		9,790,368
Accretion of Series B redeemable convertible preferred stock		$ 2,894,885